YN350233 Rhoifolin

Rhoifolin is a flavone glycoside isolated fromCitrus gr and is(L.) Osbeck leaves. Rhoifolin is beneficial for diabetic complications through enhanced adiponectin secretion, tyrosine phosphorylation ofinsulin receptor-β and glucose tra...

YN350233 Rhoifolin 17306-46-6

Rhoifolin is a flavone glycoside isolated fromCitrus gr and is(L.) Osbeck leaves. Rhoifolin is beneficial for diabetic complications through enhanced adiponectin secretion, tyrosine phosphorylation ofinsulin receptor-β and glucose tra...

YN350229 Corynoxeine 630-94-4

Corynoxeine, which could be isolated from Uncaria rhynchophylla, is a useful and prospective compound in the prevention and treatment for vascular diseases. It is a potent ERK1/2 inhibitor of key PDGF-BB-induced VSMC ...

YN350250 Methylnissolin 73340-41-7

Methylnissolin (Astrapterocarpan), isolated fromAstragalus membranaceus, inhibitsplatelet-derived growth factor (PDGF)-BB-induced cell proliferation with an IC50 of 10μM. Methylnissolin inhibits PDGF-BB-induced phosphory...

YN360003 BAY-876 1799753-84-6

BAY-876 is a potent and selective GLUT1 inhibitor (IC50=0.002 μM) with a selectivity factor of >100 against GLUT2, GLUT3, and GLUT4.

YN350173 Ravoxertinib 1453848-26-4

Ravoxertinib (GDC-0994) is an orally bioavailableERKkinase inhibitor with an IC50 of 6.1nM and 3.1nM forERK1 and ERK2, respectively.

YN350219 Honokiol 35354-74-6

Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

YN350174 Ravoxertinib hydrochloride 2070009-58-2

Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally bioavailable inhibitor selective forERKkinase activity with IC50 of 6.1nM and 3.1nM forERK1 and ERK2, respectively.

YN320045 PHCCC 179068-02-1

PHCCC is aGroup I mGluRantagonist with an IC50 of 3μM. PHCCC is a selective positive modulator ofmGlu4 receptor. Antiparkinsonian effect.

YN340274 Mogrol 88930-15-8

Mogrol is a biometabolite of mogrosides, and acts via inhibition of theERK1/2 and STAT3pathways, or reducingCREBactivation and activatingAMPKsignaling.

YN320446 8-OH-DPAT 78950-78-4

8-OH-DPAT is a potent and selective5-HTagonist, with apIC50 of 8.19 for 5-HT1A and a Ki of 466nM for 5-HT7; 8-OH-DPAT weakly binds to 5-HT1B (pIC50, 5.42), 5-HT (pIC50<5).

YN330168 PD98059 167869-21-8

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK does not directly inhibit ERK1 or ERK2.

YN321377 Lurasidone 367514-87-2

Lurasidone is a second-generation antipsychotic agent that exhibits full antagonism at dopamine D2 and serotonin 5-HT2A receptors with binding affinities Ki = 1 nM and Ki = 0.5 nM, respectively. It also has high affinity for serot...

YN320968 SB-269970 hydrochloride 261901-57-9

SB269970 HCl is a hydrochloride salt form of SB-269970, which is a 5-HT7 receptor antagonist with pKi of 8.3, exhibits >50-fold selectivity against other receptors.

YN370456 VER-155008 1134156-31-2

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.